Eylea®
Showing 1 - 25 of >10,000
Macular Degeneration (AMD) Post-marketing Surveillance in Japan
Completed
- Macular Degeneration
- Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)
-
Multiple Locations, Japan(unnamed)
Jan 9, 2023
Chorioretinal Vascular Disease Trial (ABP 938, Aflibercept)
Not yet recruiting
- Chorioretinal Vascular Disease
- ABP 938
- Aflibercept
- (no location specified)
Jan 20, 2023
Eylea in Babies Born Too Early Who HaveCondition of Eye Where
Not yet recruiting
- Retinopathy of Prematurity
- +2 more
- Aflibercept (Eylea, BAY86-5321)
-
Multiple Locations, JapanMany locations
Jan 20, 2023
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) Trial (aflibercept 8 mg PFS)
Not yet recruiting
- Diabetic Macular Edema (DME)
- Neovascular Age-Related Macular Degeneration (nAMD)
- aflibercept 8 mg PFS
- (no location specified)
Aug 3, 2023
Aflibercept Injection in Japanese Neovascular Glaucoma (NVG)
Recruiting
- Neovascular Glaucoma
- Aflibercept (Eylea, BAY86-5321)
-
Multiple Locations, JapanMany locations
Aug 17, 2022
Wet Age-related Macular Degeneration Trial in Beijing (Aflibercept)
Completed
- Wet Age-related Macular Degeneration
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Apr 19, 2022
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration Trial in Tehran (Aflibercept (CinnaGen Co, Iran),
Completed
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Aflibercept (CinnaGen Co, Iran)
- Aflibercept (Regeneron, USA)
-
Tehran, Iran, Islamic Republic ofFarabi Hospital
Oct 16, 2022
CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea
Active, not recruiting
- AMD
- Exudative Macular Degeneration
-
Bordeaux, France
- +4 more
Dec 2, 2022
g Medical Records to Learn More About Treat-and-extend With
Completed
- Neovascular Age-related Macular Degeneration
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
-
Multiple Locations, BelgiumMany Locations
Jun 9, 2022
Diabetic Macular Edema Trial in Beijing (9MW0813, Aflibercept)
Recruiting
- Diabetic Macular Edema
-
Beijing, Beijing, ChinaBeijing tongren hospital affliated to capital medical university
Apr 5, 2022
Diabetic Macular Edema Trial in Beijing (9MW0813, Aflibercept)
Completed
- Diabetic Macular Edema
-
Beijing, Beijing, ChinaBeijing tongren hospital affliated to capital medical university
Apr 5, 2022
Wet Age-related Macular Degeneration Trial (SCB-420, Aflibercept)
Withdrawn
- Wet Age-related Macular Degeneration
- (no location specified)
Apr 12, 2022
Wet Macular Degeneration Trial in Prague (Aflibercept 40 MG/ML [Eylea], Brolucizumab-Dbll 120 MG/ML [Beovu], Ranibizumab 6 MG/ML
Withdrawn
- Wet Macular Degeneration
- Aflibercept 40 MG/ML [Eylea]
- +2 more
-
Prague, CzechiaDepartment of Ophthalmology, Faculty hospital Kralovske Vinohrad
Aug 7, 2022
Exudative Age-related Macular Degeneration Trial in United States (RBM-007 Injectable Solution, Aflibercept, Sham)
Completed
- Exudative Age-related Macular Degeneration
- RBM-007 Injectable Solution
- +2 more
-
Phoenix, Arizona
- +7 more
Feb 5, 2022
Polypoidal Choroidal Vasculopathy Trial in Singapore (Aflibercept + reduced fluence photodynamic therapy (RF-PDT), Aflibercept +
Recruiting
- Polypoidal Choroidal Vasculopathy
- Aflibercept + reduced fluence photodynamic therapy (RF-PDT)
- Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)
-
Singapore, Singapore
- +2 more
Nov 14, 2022
Diabetic Macular Edema, Diabetic Retinopathy Trial (4D-150 IVT, Aflibercept IVT)
Not yet recruiting
- Diabetic Macular Edema
- Diabetic Retinopathy
- 4D-150 IVT
- Aflibercept IVT
- (no location specified)
Jun 26, 2023
Metastatic Uveal Melanoma Trial in Tampa (ZIV-Aflibercept, Cemiplimab)
Recruiting
- Metastatic Uveal Melanoma
-
Tampa, FloridaMoffitt Cancer Center
Nov 2, 2023
Chorioretinal Vascular Disease Trial in Houston, The Woodlands (Intravitreal Aflibercept Injection (IAI))
Completed
- Chorioretinal Vascular Disease
- Intravitreal Aflibercept Injection (IAI)
-
Houston, Texas
- +1 more
Aug 18, 2021
naïve Age-related Macular Degeneration of Neovascular Type and
Completed
- Age-related Macular Degeneration
- Data extraction from medical files
-
Brussels, BelgiumCHU Brugmann
Mar 7, 2022
Neovascular Age-related Macular Degeneration Trial in Graz (Aflibercept 40 MG/ML, Faricimab 120 MG/ML)
Recruiting
- Neovascular Age-related Macular Degeneration
- Aflibercept 40 MG/ML
- Faricimab 120 MG/ML
-
Graz, Styria, AustriaDepartment of Ophthalmolgy, Medical University Graz
Jul 3, 2023
Neovascular Age-related Macular Degeneration Trial in Phoenix (CLS-AX, Aflibercept)
Recruiting
- Neovascular Age-related Macular Degeneration
-
Phoenix, ArizonaRetinal Research Institute, LLC
Jun 4, 2023
Use of Aflibercept Injections Into Eye for Treatment of Eye
Recruiting
- Retinal Disease
- Aflibercept (BAY86-5321, Eylea)
-
Multiple Locations, MexicoMany locations
Aug 22, 2022
Wet Age-related Macular Degeneration Trial in Beijing (RC28-E, Aflibercept)
Recruiting
- Wet Age-related Macular Degeneration
-
Beijing, Beijing, ChinaBeijing Hospital
Feb 3, 2023